15/10/02说明:此前论坛服务器频繁出错,现已更换服务器。今后论坛继续数据库备份,不备份上传附件。

肝胆相照论坛

 

 

肝胆相照论坛 论坛 学术讨论& HBV English 条条大路通罗马?
楼主: shiweibuyi
go

条条大路通罗马? [复制链接]

Rank: 9Rank: 9Rank: 9

现金
9671 元 
精华
帖子
12248 
注册时间
2009-10-14 
最后登录
2021-11-25 

神仙眷侣 如鱼得水 翡翠丝带 健康之翼

31
发表于 2010-2-11 13:08 |只看该作者
好样的,等仔细看
温故中知新

Rank: 9Rank: 9Rank: 9

现金
9671 元 
精华
帖子
12248 
注册时间
2009-10-14 
最后登录
2021-11-25 

神仙眷侣 如鱼得水 翡翠丝带 健康之翼

32
发表于 2010-2-11 13:11 |只看该作者
原帖由 lemonades 于 2010-2-11 09:57 发表
From medhelp hbv forum:
by stefano170669


tenofovir (viread) is much stronger than baraclude and has 0 resistance but have some mild sides in 1% cases of kidney toxicity and bone demineralization.ser ...


thanks.
温故中知新

Rank: 4

现金
415 元 
精华
帖子
70 
注册时间
2009-6-29 
最后登录
2010-5-9 
33
发表于 2010-2-11 13:43 |只看该作者
附件: 你需要登录才可以下载或查看附件。没有帐号?注册

Rank: 7Rank: 7Rank: 7

现金
4537 元 
精华
帖子
1886 
注册时间
2009-8-29 
最后登录
2018-2-4 
34
发表于 2010-2-11 16:11 |只看该作者
绝望中探索希望

Rank: 7Rank: 7Rank: 7

现金
467 元 
精华
帖子
2219 
注册时间
2004-11-24 
最后登录
2011-12-19 

色女勋章 心灵港湾 旺旺勋章

35
发表于 2010-2-12 08:19 |只看该作者
感谢shiweibuyi的分享,同时佩服楼主的态度。
人的价值=尊严+爱

Rank: 4

现金
415 元 
精华
帖子
70 
注册时间
2009-6-29 
最后登录
2010-5-9 
36
发表于 2010-2-23 09:38 |只看该作者
附件: 你需要登录才可以下载或查看附件。没有帐号?注册

Rank: 4

现金
415 元 
精华
帖子
70 
注册时间
2009-6-29 
最后登录
2010-5-9 
37
发表于 2010-3-2 09:53 |只看该作者

2010年2月28日:树突细胞治疗有望降低乙肝病毒。

2010年2月28日:树突细胞治疗有望降低乙肝病毒。

四男性乙肝病人,30到60岁,常用治疗无效,受试树突细胞治疗,一个月后HBVDNA和ALT均降,2个病人HBVDNA转阴。

Dendritic Cell Treatment Shows Promise for Decreasing Viral Loads in Chronic Hepatitis B: Presented at AAAAI
By Carole VanSickle Ellis

NEW ORLEANS -- February 28, 2010 -- Physician's treating patients with chronic hepatitis B virus (cHBV) may be able to turn a decade's worth of cancer research to their advantage when it comes to using dendritic cells (DCs) in immune therapy protocols for these patients, researchers said here on February 27 at the 2010 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting.
According to Leonid Titov, MD, Research Institute for Epidemiology and Microbiology, Minsk, Belarus, and colleagues, since patients with cHBV have impaired dendritic cell function, their immune systems are not able to produce mature DCs.
However, a new maturation protocol being investigated for safety and efficacy at the Research Institute for Epidemiology and Microbiology, allows for a new form of DC therapy similar to conventional DC-based cancer therapies, for patients with cHBV.
The 4 patients were male, aged 30 to 60 years, and had polymerase chain reaction-proven cHBV for several years. They had been unsuccessfully treated using standard protocols. Using peripheral blood taken from the patients, DCs were prepared and then injected into the forearms of the patients. Once injected, the patients were monitored for 7 days and then discharged from the hospital. The other 2 injections were performed in the outpatient department at 3-week intervals.
The number of DCs generated from 50 mL of blood was limited by the number of circulating monocytes and the efficiency of isolation procedures. The cultures were tested for sterility twice and were found free of microbial contaminants.
All of the patients tolerated the injections well, and no local or systemic side effects were observed. All patients also demonstrated a clinical response to therapy, typified by a significant decrease in viral load and alanine aminotransferase levels 1 month after the DC injections.
Three of the 4 patients had an increase in CD4/CD8 index and CD3-CD16+, and CD3-CD56+ cell count. These patients also showed elevated expression of CD28 by T cells after the treatment. One month after the study, HBV viral load was undetectable in 2 of the 4 patients. The other 2 showed a significant reduction.
The study indicated that there are no adverse effects of DC-based treatment of patients with cHBV. In addition, short-term clinical efficacy of DC-based immunotherapy was evident in all 4 patients.
The authors noted that advanced, multicentre trials will be needed to allow for longer observation of patients in order to prove the sustained impact of the treatment.
It should be noted that the same DC generation method could be implemented to obtain antigen-specific DC from patients' blood with hepatitis C. These cells can be loaded with hepatitis C virus nonstructural proteins to aid in immune-based cellular therapy.
[Presentation title: Safety and Short Term Efficacy of Dendritic Cell Immune Therapy in Patients With Chronic Hepatitis B. Abstract 50]
已有 1 人评分现金 收起 理由
lemonades + 5 精品文章

总评分: 现金 + 5   查看全部评分

Rank: 8Rank: 8

现金
663 元 
精华
帖子
403 
注册时间
2010-2-1 
最后登录
2024-3-2 
38
发表于 2010-3-2 11:04 |只看该作者
好!

希望能最终成功!

Rank: 4

现金
415 元 
精华
帖子
70 
注册时间
2009-6-29 
最后登录
2010-5-9 
39
发表于 2010-3-4 13:42 |只看该作者

贝壳大夫的仪器可使病毒等失灵,是真就好.

贝壳大夫的仪器可使病毒等失灵,是真就好,May be too good to be true.

Our new Magnetic Pulser is heavy duty and Australian designed and manufactured. It follows Dr. Robert Beck’s cleansing principles. Dr. Beck says it disables all viruses, bacteria, fungi, microbes, germs, pathogens and parasites. Use the Magnetic Pulser instead of the Blood Cleaner where blood does not flow. The magnetic Pulser can also be used with pets and animals.

A blood “zapper” or cleaner supplies electrical current to the body from an external source by conduction, but the Magnetic Pulser induces currrent directly into the tissue without physical contact. For therapy, permanent magnets are largely useless (some may argue). An effective “magnetic therapy” requires a time varying magnetic field which is achieved by using pulse technology. This magnetic energy induces electrical current and voltage in any conductor in its vicinity (human tissue is a good electrical conductor).

Various “magnetic” therapies have existed for a number of years but the originator of the “magnetic pulser” is Dr. Robert C. Beck. However he has not designed one from “scratch”. He has only modified and used commercial photographic flash units. Our Australian made Magnetic Pulser is designed from scratch and is not based on a flash unit or a flash tube but a high power SCR as a trigger/discharge device.

Technical details: the spacing of pulses is user selectable from 3 to 7 seconds in 1 second steps; it can be made to operate on a 12 volt battery of suitable capacity; the main capacitor (750uF/330V) hold approx. 41 joules of energy; the average peak discharge current through the magnetic coil is over 300 amp!, but the pulse duration is only 2 milliseconds; magnetic energy from the coil in each discharge is approx. 145,000 gauss; the unit is fan cooled to prevent overheating; the unit has a buzzer which sounds in ‘turn on” and automatic “turn off” (for hard of hearing).
Technical specifications: Power source*: A. 12 - 18V AC (from supplied transformer) B. 12V external battery--7AH or larger (optional) Battery charging: limits set at: 12.2V min.--14V max, automatic, can be left on indefinitely set to fully charge a 7AH sealed lead acid battery in 20 hours (this can be changed to other values for other battery sizes) • DC - DC converter output: 330V (adjustable)• Main capacitor: 750uF, 330V (Photoflash, made to order)• Energy in each discharge: 41 joules (approx.) • Discharge time: 2msec. (approx.) • Magnetic energy from coil in each discharge: approx. 145.000 gauss (calculated) • Peek current in coil for each discharge: 300A (average) • Pulse rate**: user adjustable from 3 to 7 seconds in 1 second steps (3-4-5-6-7) • Timer: 10 minutes. (Used mainly as a ‘time out’ in case the unit is not switched off after use.) • Buzzer: sounds on ‘turn on’ and automatic ‘turn off’ but not on manual ‘turn off’ Fan cooled to prevent overheating. Should the fan fail, (or should the unit be operated for lengthy periods) the unit then enters into a second self protecting mode. When the capacitor’s temperature reaches a critical point, it will no longer charge to the full voltage and the unit will shut down. When it cools down sufficiently, it will resume normal operation.
*, ** Note: to ensure that the discharged energy in each pulse is the same, the capacitor is not allowed to discharge before it is fully charged. (to 330V)
Should a power source (transformer or battery) be of smaller capacity than the one supplied, it may not be able to fully charge the capacitor in the time selected. Therefore, the interval between discharges will be lengthened. The system will await the arrival of the next timing pulse. In practical terms it means that it may only discharge on every second, third or even fourth multiple of the ‘pulse rate’ setting.

Rank: 4

现金
415 元 
精华
帖子
70 
注册时间
2009-6-29 
最后登录
2010-5-9 
40
发表于 2010-3-6 11:41 |只看该作者

二氧化氯真有如此奇效就好了!30滴算什么!!

Chlorine Dioxide (Miracle Mineral Solution)

In the case of a liver condition, such as hepatitis, one almost always gets nauseous. The reason for this is that the liver begins to expel the poisons as the chlorine dioxide begins to destroy them, but it also cures the condition in record time. One lady with hepatitis C did exactly what I told her not to do. Instead of taking 2 drops at first, to be certain she killed the hepatitis she used 30 drops, added the vinegar, waited 3 minutes, and added it to apple juice. It made her sick for 3 days. She then put the MMS aside and did not touch it for 8 months. She thought that since it had made her so sick that it didn’t work, but when she finally decided to go to the doctor, he could find no hepatitis in her body. Both were amazed. I have given it to many people with one of the hepatitis diseases, A, B, or C. I can guarantee that 30 drops will make any hepatitis patient feel very sick, but it will also usually cure them. However, that is not the way to do it. A hepatitis patient should never start out with more than 2 drops. Normally, they will not feel any nausea with this dosage, and if they slowly increase the drops until they can take 15 drops three times a day without nausea, they will usually test negative for hepatitis of all kinds. I should mention at this time that nothing is an absolute guarantee. Each person is different and there can be extenuating circumstances that change the outcome.
‹ 上一主题|下一主题
你需要登录后才可以回帖 登录 | 注册

肝胆相照论坛

GMT+8, 2024-11-1 11:30 , Processed in 0.022354 second(s), 12 queries , Gzip On.

Powered by Discuz! X1.5

© 2001-2010 Comsenz Inc.